Navigation Links
Growth factor predicts poor outcome in breast cancer
Date:8/29/2008

The response to insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts an aggressive tumor that is less likely to respond to treatment, said researchers at Baylor College of Medicine in a report that appears in the current issue of the Journal of Clinical Oncology. The finding gives impetus to the movement to tailor cancer treatments to attributes of the various tumors.

"These findings come at a critical time," said Dr. Adrian Lee, associate professor in the Lester and Sue Smith Breast Center at BCM. "Our goal is to identify biomarkers that will help predict which patients will respond to therapy against insulin-like growth factor. Several inhibitors of the IGF pathway are in patient studies right now. There's a large movement to understand which patients will respond to these drugs. This is a step toward that goal"

In this study, Lee and his colleagues stimulated breast cancer cells with IGF-I in the laboratory and defined how more than 800 genes in the cells responded to the growth factor. They then examined samples of patient breast tumors with this "gene signature" and correlated the gene signatures with the fate of the patients.

"We have technology now to allow us to globally assess what IGF is doing in breast cancer at the whole gene expression level," said Lee. "This is one of the first studies to do that. We know that IGF is bad in cancer, but now we can globally understand it in a more comprehensive manner. It could lead to finding biomarkers for patients response" to breast cancer treatments.

"We found that IGF-I is a major regulator of cell growth and cell survival," said Lee. "It also regulates DNA repair."

This has major implications for anti-cancer treatments that seek to cause DNA damage and tumor cell death.

"If you have something regulating DNA repair, you want that turned off," said Lee.

They found that tumors in which IGF (insulin-like growth factor) affected the way in which genes were activated or translated into messages were more aggressive and more likely to grow. They also found that the effect of IGF was independent of whether the tumor was affected by estrogen or not.

"This is very important," said Lee. "Once patients are resistant to hormone treatment (as with tamoxifen), their treatment options are limited. A treatment that inhibited receptors for IGF might give them another option."

Currently, the Breast Center is studying the effects of an IGF receptor antibody combined with a drug called exemestane (Aromasin or an aromatase inhibitor that blocks estrogen production) in postmenopausal women. One group of women take the combination and the other takes exemestane.

Bioinformatics the ability to analyze large amounts of data proved key to the study, said Lee. In fact, the first author, Dr. Chad J. Creighton of BCM, is a bioinformatician, said Lee.


'/>"/>

Contact: Kimberlee K. Norton
kknorton@bcm.edu
713-798-4710
Baylor College of Medicine
Source:Eurekalert

Related biology news :

1. Heavy metal link to mutations, low growth and fertility among crustaceans in Sydney Harbor tributary
2. Hydrogels provide scaffolding for growth of bone cells
3. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
4. Old growth giants limited by water-pulling ability
5. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
6. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
7. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
8. Embryo biopsy does not affect early growth and risk of congenital malformations in PGD/PGS babies
9. Growth hormones link to starvation may be clue to increasing life span, researchers find
10. Blue light used to harden tooth fillings stunts tumor growth
11. Scientists find potential protein biomarkers for growth hormone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):
(Date:4/28/2017)... , ... April 28, 2017 , ... ... organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine ... 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs of ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... today announced their digital pathology technology has the potential to eliminate subjectivity in ... centers in The Netherlands as part of the 2017 ISBI CAMELYON Digital ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead Publishers is pleased to ... coming to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, ... advances in the treatment of various types of pain. There are also extended ...
(Date:4/27/2017)... Orleans, La. (PRWEB) , ... ... ... Monitoring Technologies today announced a comprehensive rebrand and a name change to ... for the industrial and laboratory monitoring of polymer and biopharmaceutical manufacturing processes ...
Breaking Biology Technology: